The Curious Case Of Booze-Free Beverages
JW Wiseman, founder of Curious Elixirs, has pioneered an original approach to the non-alc space.
What began as a personal quest to drink less has blossomed into a pioneering force in the non-alcoholic beverage industry. In this interview, JW Wiseman, founder of Curious Elixirs, shares the decade-long journey of his brand, from kitchen experiments to navigating market shifts and shaping the future of social drinking. We sat down to discuss the evolution of his innovative elixirs, unique marketing strategies, and the unconventional distribution model that has propelled Curious Elixirs to the forefront of a booming category.
Dave Knox: This year is your 10-year business anniversary with Curious Elixirs. What led you to launch the business?
JW Wiseman: The short answer is I was drinking too much. While working at Thrillist, I had 20 drinks one night and didn't even have a hangover the next day. That experience started me on the path to launching the first craft non-alcoholic cocktail company. I was a big cocktail enthusiast, loving Negronis, Blood and Sands, and other innovative drinks. But as I changed my relationship with alcohol, I couldn't find anything adult to drink. Curious Elixirs started with me tinkering in my kitchen, then slowly realizing there might be a business here.
Knox: How did you go from tinkering in your home kitchen to bottling and tweaking formulas, transforming a hobby into a professional business?
Wiseman: It was a slow burn. I started mixing different things in my kitchen, trying to make a non-alcoholic Negroni or Dark and Stormy. Then I brought my creations to parties. At the opening party of Playland Motel, a hotel I co-owned, I put out a giant carafe labeled Curious Elixir No. 1. People didn't realize it had no alcohol and drank it more than the mezcal or other cocktails. I thought, "People are drinking this because it's delicious." That was the "aha!" moment, realizing it had a much bigger audience than just me and my friends who were drinking less.
That led me to consider a Kickstarter, find a commercial kitchen, and research the market. I discovered that over 75 million adult Americans didn't drink alcohol, and another 90 million had two or fewer alcoholic drinks a week—these numbers were from over a decade ago and have only increased. The term "sober curious" didn't even exist when we started. The process was slow at first, taking a couple of years to piece together that this should be a business and a huge opportunity. It wasn't until I saw Martha Stewart speak in 2015 that I decided to turn this into a real business.
Knox: When you first put Curious Elixir No. 1 on the bar, how has the formula changed since then? Did that original one include adaptogens, which you're known for today?
Wiseman: Yes, Curious Elixir No. 1 had functional herbs. After leaving Thrillist, I started a marketing company for growth-stage clean food companies. One client was Daily Harvest, which opened my eyes to the power of adaptogens and functional herbs to support the body. I saw a market for these remedies—herbs with a long history of traditional usage. Rhodiola rosea particularly stood out, with its multi-thousand-year history, first referenced in 77 AD. It can help balance cortisol and aid serotonin and dopamine absorption.
Adaptogens were built into Curious Elixirs from day one. I felt this could be Curious Elixirs' "secret mission": be flavor first, and as the market matured, we could talk more about the functions and how adaptogens support the body. That's what we're increasingly known for. But initially, we focused on making the best possible drinks with depth, complexity, and sophistication to appeal to beverage directors, sommeliers, and aficionados.
Knox: Balancing education about the non-alcoholic space and the use and safety of adaptogens must have been challenging at the early leading edge of these trends. How did you approach this?
Wiseman: For the first five years, adaptogens were very secondary, almost tertiary, messaging. It was like being vegan 30 years ago—people didn't know what it meant, and many still don't quite understand adaptogens. So, we went heavy on flavor first for the first five years. That's why Daniel Boulud restaurants, Alinea in Chicago, and other world-class establishments picked us up. We focused on creating the world's best non-alcoholic drinks, which hadn't been done before. It's only been in the last two or three years, from 2020 onward, that people started to realize there's a whole class of plants that can boost the body or reduce adrenal fatigue. That's when things picked up in the adaptogen space. Now you see ingredients like Lion's mane, which is in our newest Elixir, Curious Zero, a Lion's mane lager. These ingredients are having a moment, but it's been years in the making.
Knox: You have an amazing marketing background, working with brands like Daily Harvest and trendsetters like Thrillist. How has that influenced Curious Elixirs' branding and marketing?
Wiseman: Taking the Thrillist example, we described Thrillist's voice as if Han Solo were your friend telling you about the coolest spot. It's like having a cool older brother or a friend who's more in the know, but always with a fun and whimsical style. If someone entertains you while educating you, it performs better, sticks better, and reaches more hearts and minds with a sense of humor. We took that to heart. When we launched our Kickstarter, we did a Game of Thrones spoof video that got over six million views on Facebook. That was huge for us in breaking through the clutter, especially when video was relatively new on that platform. I think incorporating an eye and voice from comedy is incredibly helpful for breaking through clutter, and that's something we've always baked into the brand.
Knox: Let's discuss funding. You started with Kickstarter. How have you approached your funding journey as you've grown the business over the last decade?
Wiseman: Because we were so early and this segment of the beverage industry literally didn't exist before Curious, we decided not to take outside capital. We did it ourselves, using Kickstarter to break through the noise, create a time-boxed campaign to get our first 500 buyers, and secure initial press and validation. Since it was so early, we didn't need to raise a lot of money. Because we make a luxury item—something at the high end of what's now a real segment of the beverage industry—we've been running on cash flow ever since. Profits are reinvested to grow the team, expand distribution, secure multiple warehouses, reduce costs over time, and continuously refine our recipes. We never stop refining, just like with business practices or marketing; we always strive to make our drinks better.
Knox: Regarding your distribution strategy, many brands go straight to large retailers. You've taken a different approach. What led to your choices in distribution and driving consumption and awareness?
Wiseman: A lot of this comes from the Warren Buffett school of "look at what everybody else is doing and do the opposite." Everyone was launching celebrity tequila or going retail-first. We decided to go direct-to-consumer (DTC) first because we believed we'd build an army of ambassadors and then determine distribution based on where our highest quality customers were. Once we saw a concentration of great customers in Michigan, for instance, we knew we should have a distributor there.
I also started with DTC because it's what I knew. At Thrillist, I was also head of marketing for JackThreads, an e-commerce clothing company. I learned e-commerce and DTC marketing strategies at scale, taking JackThreads from a few million to $55 million in annual revenue. It was leaning into my strengths. Also, a retail-first strategy requires a ton of capital. In the early days, without raising money, we needed a capital-light approach. We needed to sell all our product, reinvest in the next production run, and keep going for years while refining our practices for efficiency.
Now, we're finally moving beyond the self-distribution we've done for 10 years. We're in a few thousand doors across the country. To get from 2,000 to 20,000 or 50,000 retailers, we'll need the best distributors in the business. That's a big part of the current and next few chapters for Curious: working with best-in-class distributors who care about craft, serve their customers well, and understand that this growing segment is not a fad; it's a seismic shift in how we consume beverages.
Knox: Are there any places in your current distribution footprint that you're most proud of or that would surprise people?
Wiseman: Some came to us organically, like Alinea in Chicago reaching out. The French Laundry, within our first couple of years, had a sommelier targeted by an Instagram ad who became a wholesale client. These things surprised us. Another inbound surprise was the Four Seasons on Oahu—we didn't have a broker pitching a high-end hotel; they came to us. I think that's because we've focused on making the world's best booze-free beverages, and the reviews speak for themselves. Being named Best Non-Alcoholic Drinks five years in a row by the New York Times or being the official non-alcoholic partner of the James Beard Foundation attracts these "wow, I can't believe we're carried there" moments.
But it's also the small ones. Not just the big names, but places like a local winery in Asheville, North Carolina. The fact that Curious does well there warms my heart because that's our mission: to transform how we drink socially. When your local craft brewery or winery carries Curious for an inclusive drink menu for friends who don't want alcohol, that's how we're changing culture. The more small wins we have, the more we change culture.
Knox: Your marketing and social media presence are built around the concept of curiosity and mystery. Why are those at the heart of your marketing strategy?
Wiseman: Because that's where it all started. Curious Elixirs began with the question: What would a high-class drink without alcohol look like? And then: What if that drink could make my body feel better than feeling awful the next day? Questions lead us down the path of progress. That's why it had to be baked in from the start.
Knox: How have you creatively brought that concept to life for consumers?
Wiseman: We do super fun stuff. For example, when we launch a new flavor, we always have a mystery pre-sale. We announce the number of the next elixir—it's clear we've been doing this for 10 years because we have Curious 1 through 9, and now Curious Zero for our 10th. The mystery pre-sale launches with no hints about the flavor, just some education on the function. For Curious Zero, we said, "This will lift your libido and boost your brain with adaptogens." Our diehard fans love it; they enjoy the unboxing moment where they don't know what they'll get.
Another fun, Curious initiative was the Great Curious Cocktail Party. This was our third year, and happened on May 14th, 2025. We host 100 parties in 100 cities on one night—a constellation of celebrations. It's wild to see the hosts' creativity. We put out a call for hosts, saying, "Tell us what you want to do, whether it's five people or 50." We've had everything from beach bonfires in San Diego to speed dating in Buckhead, Atlanta, to backyard concerts in Nashville, Bollywood movie nights, comedy nights, and ballroom dancing. People devise all sorts of ways to celebrate what being curious means to them. We host our own party at Club Curious, our sober speakeasy in Williamsburg, Brooklyn, and have a toast across the country with over 100 parties going on simultaneously, celebrating life, because life is more interesting with less booze and more creativity.
Knox: For the Great Curious Cocktail Party, how does it work? They submit ideas, and then what's the brand's involvement beyond marketing and promoting?
Wiseman: We had about 400 people apply to be party hosts. Our marketing team approved just over 100, plus over 50 retailers, so we had 150 parties this year. We sent them a party pack with Curious hand fans, other party materials, and four cases of Curious Elixirs. We provided the drinks, they provided the people. We even had a Spotify playlist and did a live stream at 9:00 PM Eastern Time on May 14th. So, it's a lot of coordination from the marketing and wholesale teams working with retailers. We even had a webinar on how to throw a Great Curious Cocktail Party to help people understand how to serve them. Curious Elixirs are easy to serve: just flip it before you sip to remix ingredients, then pour over ice. Garnish with abandon—add whatever you like. We have suggestions, but we encourage people to tinker. That's how this all started, with me tinkering, and it's important for people to know it's okay for them to tinker too.
Knox: The brand has achieved enormous recognition. The category has changed significantly with many new competitors. How have you stayed at the forefront of brand awareness and remain the first choice for consumers?
Wiseman: We just focus on what we're doing. It's great that so many new non-alcoholic beverages have emerged; it validates that this category should exist. There should be many quality non-alcoholic options. How we've distinguished ourselves: A dozen years ago, I knew making Curious would change beverage culture. Taking that to its logical extreme means hundreds of options. If you focus on making the best version of your specific product, you don't have competition. You focus on yourself and your customers.
That also ties into why we don't have investors—we're only accountable to our customers. I read every review, good or bad, and listen to feedback to make our products as good as possible, while balancing factors like sugar content. One key learning is that customers want delicious flavor but not a lot of sugar, especially those seeking healthier lifestyles. We've found ways to balance natural fruit with bitter and herbaceous elements. We're obsessed with quality. No other brand gets blood oranges from Sicily for a spritz.
Our numbering system, Curious Zero through 9, is a nod to cocktail culture with famous drinks like Corpse Reviver No. 1 or Pimm's No. 1. It's an homage to the history of brewing, fermentation, distillation, and mixology that inspired me. When it comes to the non-alcoholic sector at large, we're just focused on making the world's best booze-free beverages, and we think it's great that many other players have entered the space.
A word of caution: just because something is non-alcoholic doesn't mean it's good for you. Many companies claim to be healthy while using carcinogens, preservatives, and other problematic ingredients. Always read your labels. It takes time and research, but it's crucial as the non-alcoholic industry evolves. We're obsessed with high quality, not using preservatives, natural flavors, or other shady stuff.
Knox: The business is 10 years old, and you just released Curious Zero, your 10th formula. Where does the business go from here? What do you envision for the next 10 years of innovation in flavor, distribution, and beyond?
Wiseman: There will definitely be more innovation in the non-alcoholic sector. People will become more curious about how they feel after drinking something and what supports their body. For Curious Elixirs specifically, you'll see us in more restaurants, performance venues, and regions. I can't predict the next 10 years exactly, but it's getting easier for Curious to get on shelves and behind bars. Bartenders and restaurateurs are realizing they can make more money by serving the most followed brand in non-alcoholic. It has a gravitational pull now, which will continue to help us transform our drinking culture as the years go by.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Buzz Feed
an hour ago
- Buzz Feed
Lizzo Talks About Using Ozempic For Weight Loss
There's no point in stressing out over speculation and rumors regarding Lizzo — she's an open book. On a June 19 episode of the Just Trish podcast, Lizzo admitted that she tried Ozempic and other GLP-1 drugs, which are used to regulate type 2 diabetes and obesity, at one point in her "weight release" journey. Over the years, the "Truth Hurts" singer has been rather forthcoming with her fitness journey, documenting it on social media and sharing her progress with her fanbase. "I tried everything," she told Trisha Paytas. "Ozempic works because you eat less food, yeah? So if you eat right, it makes you feel full. But if you can just do that on your own and get mind over matter, it's the same item." In the podcast, Lizzo shut down critics of Ozempic and GLP-1 drugs, noting that people are not "cheating" by using the products. "It's not easy," Lizzo said. "It's a drug to help somebody with something they're struggling with. I think people... it's their way of being fat phobic when you're telling someone they're cheating." "They tell people they're cheating by getting that weight loss surgery. I heard about that weight loss surgery. That shit sounds very hard actually. A lot people felt like they almost died on the table, and they got so sick after getting the weight loss surgery. That shits not easy." "I feel like people just like to make fun of fat people. Whether you're big or small or got small, they like to make fun of us," she said. Lizzo claimed that she started noticing different results when adding meat back into her diet. "What did it for me is it was not being vegan," she said. "Because when I was vegan, I was consuming a lot of fake meats, I was eating a lot of bread, I was eating a lot of rice and I had to eat a lot of it to stay full." In her opinion, the "fake sugar and weird shit" in processed foods was holding her back, causing her to eat 3,000 to 5,000 calories a day. "When I started actually eating whole foods and eating, like, beef and chicken and fish," she said, "I was actually full and not expanding my stomach by putting a lot of fake things in there that wasn't actually filling me up." "I feel like I worked really, really hard and I was intentional what I did with my body," she added. And that's that! Take that shame somewhere else because Lizzo doesn't play that. Watch the full episode of Lizzo on the Just Trish podcast here.
New York Post
6 hours ago
- New York Post
5 foods that naturally stimulate the ‘Ozempic hormone' — without drugs
Want to shed pounds without getting poked? Your fork might be the fix. While GLP-1 drugs like Ozempic and Wegovy have taken the weight-loss world by storm, there are some everyday foods that offer similar benefits naturally — no needle required. 'No one food is a magic bullet for anything, but getting a balanced diet rich in nutrition-dense foods is a great way to manage your appetite and feelings of being full,' Dr. Amir Khan, a general practitioner, said in an Instagram video. Advertisement Khan broke down five foods to add to your diet if you're looking to naturally boost your levels of GLP-1, the hunger-controlling hormone that these trendy drugs are designed to mimic. An added bonus: These foods are also packed with nutrients that benefit your whole body, not just your waistline. But first: what is GLP-1? Advertisement GLP-1 is a hormone released by the small intestine after you eat, according to the Cleveland Clinic. It plays several key roles in how the body processes food, including triggering insulin production to turn meals into energy and lower blood sugar levels. 5 About 12% of US adults have tried a GLP-1 drug. millaf – Advertisement It also suppresses glucagon, a hormone that raises blood sugar, and slows stomach emptying, which helps you feel fuller for longer. GLP-1 drugs mimic this natural process by curbing appetite and reducing food intake, often leading to weight loss. But according to Khan, some kitchen staples can produce similar effects. #1 Eggs Packed with protein and monounsaturated fats, eggs have been shown to help boost GLP-1 secretion. Advertisement 'Egg whites in particular are thought to be beneficial to GLP-1 release,' Khan said. 5 Eggs may even help trigger the release of GLP-1 and other satiety hormones. Mara Zemgaliete – A 2016 study compared a bagel breakfast to one with three eggs. The egg meal led to lower blood sugar after eating, less hunger, and reduced food intake over the next 24 hours. #2 Certain nuts Almonds, pistachios, and walnuts may help boost GLP-1 thanks to their fiber, protein, and healthy fats. These nutrients work together to slow digestion, leading to a more steady rise in blood sugar and improving insulin sensitivity. #3 High-fiber grains Grains like oats, barley and whole wheat are packed with soluble fiber, which dissolves in water and forms a gel-like substance in your gut. 5 Soluble fiber, found in oats, barley, and rye, slows down the digestion process. baibaz – Advertisement This gel slows digestion and the release of glucose into your bloodstream, preventing sugar spikes and triggering GLP-1 release. #4 Olive oil 'Studies suggest unsaturated fats, like those in olive oil, stimulate GLP-1 release better than saturated fats found in butter,' Khan explained. Olive oil also slows carbohydrate digestion, helping prevent rapid blood sugar spikes. Advertisement Its polyphenols and vitamin E provide antioxidant and anti-inflammatory benefits that support hormone regulation — including GLP-1. A 2021 review found that a Mediterranean diet rich in olive oil led to higher post-meal GLP-1 levels, improved insulin sensitivity, and lower blood sugar compared to diets high in saturated fats. #5 Some vegetables Veggies like Brussels sprouts, broccoli and carrots are loaded with fiber, which helps regulate blood sugar. Advertisement Gut bacteria break down that fiber into short-chain fatty acids, which Khan says signal gut cells to release GLP-1 into the bloodstream. 5 Vegetables are high in fiber, vitamins and minerals, which can help regulate blood sugar and GLP-1 levels. Wolfilser – A 2022 study found that eating vegetables before carbs significantly improved glucose and GLP-1 levels in people with type 2 diabetes — especially an hour after eating. America's weight problem Advertisement About one in eight US adults have tried a GLP-1 drug, according to a 2024 KFF poll. Among them, nearly four in 10 say weight loss was the primary reason. Obesity is an epidemic in America, with more than two in five adults and nearly one in five kids and teens classified as obese, per the CDC. The health fallout is huge. Obesity is a risk factor for a wide range of chronic conditions, including heart disease, type 2 diabetes, osteoarthritis, sleep apnea, kidney disease and even several cancers. But it's not just physical. Obesity can take a toll on mental health, with research showing it increases the risk of developing low self-esteem, depression, eating disorders and chronic stress. On top of that, people with obesity often face bias at school and work, taking a serious toll on their quality of life.
Business Upturn
16 hours ago
- Business Upturn
Novo Nordisk's subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
By GlobeNewswire Published on June 21, 2025, 04:34 IST Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was published in The Lancet and presented at the American Diabetes Association (ADA) Scientific Sessions. 1,2 and presented at the American Diabetes Association (ADA) Scientific Sessions. Oral amycretin phase 1 data on the safety, tolerability and weight loss potential in people with overweight or obesity was also published in The Lancet. 3 Findings from the clinical trials indicate amycretin appeared tolerable with a safety profile consistent with other GLP-1 and amylin receptor agonists.1,2,3 Bagsværd, Denmark, 20 June 2025 – Novo Nordisk announces subcutaneous amycretin data being presented at the American Diabetes Association (ADA) 85 th Scientific Sessions in Chicago, US.1 Full results of two clinical trials evaluating the safety, tolerability and weight loss potential of subcutaneous and oral amycretin in people with overweight or obesity were published today in The Lancet medical journal.1,3 Amycretin is the first treatment that combines GLP-1 and amylin receptor agonism biology in a single molecule. The published and presented results from the once-weekly subcutaneous amycretin phase 1b/2a clinical trial showed that participants who received the treatment demonstrated significantly greater weight loss across the full range of doses investigated compared to placebo. Data being presented at ADA were collected from two parts of the trial; dose escalation (amycretin 60 mg), and dose escalation and maintenance (amycretin 20 mg, 5 mg and 1.25 mg).1,2 No plateauing in weight reduction was observed at the end of treatment (ranging from 20 to 36 weeks) with all tested doses, suggesting that a longer treatment duration may potentially contribute to additional weight loss.1,2 Estimated mean change in body weight from baseline with once-weekly subcutaneous (SC) amycretin: 1,2 * Dose Treatment % Weight change % Weight change duration (SC amycretin) (placebo) 60 mg 36 weeks -24.3% -1.1%20 mg** 36 weeks -22.0% 1.9%5 mg** 28 weeks -16.2% 2.3% 1.25 mg** 20 weeks -9.7% 2.0% * If all people adhered to treatment i.e. if all people followed the planned dosing schedule for the full trial period without any treatment discontinuations. ** Administered during a 12-week maintenance period. Once-weekly subcutaneous amycretin treatment escalated up to 60 mg appeared tolerable with a safety profile consistent with other GLP-1 and amylin receptor agonists.1,2 The number of treatment-emergent adverse events (TEAEs) increased in a dose-dependent manner, were mostly gastrointestinal, and were comparable to the rate and profile of TEAEs reported in early-phase studies of GLP-1 receptor, GLP-1 receptor/gastric inhibitory polypeptide (GIP) receptor, and amylin receptor agonists.1,2 The majority of TEAEs were mild to moderate in severity and resolved by the end of the study period.1,2 Of the participants who discontinued the trial, the majority were due to non-TEAE reasons.1,2 'As pioneers in obesity innovation, we are exploring multiple biological pathways to develop potentially transformative medicines that support the individual needs and preferences of people with obesity on their weight loss journey towards overall improved health,' said Martin Holst Lange, executive vice president for Development at Novo Nordisk . 'Amycretin is the first investigational treatment that combines GLP-1 and amylin receptor agonism biology in one molecule, working on distinct pathways and offering complementary effects on appetite control. The findings published and presented today are encouraging. We are excited to advance the clinical development of subcutaneous and oral amycretin into phase 3 to assess its potential as a therapeutic option for weight management.' The published once-daily oral amycretin phase 1 clinical trial data showed that participants receiving amycretin achieved greater weight loss compared to placebo.3 After 12 weeks of treatment with amycretin up to 50 mg and up to 2 times 50 mg, participants achieved a mean change in body weight of -10.4% and -13.1% respectively, compared to -1.2% with placebo.3 There were no apparent signs of weight loss plateauing within the 12 weeks of treatment in either of these amycretin-treated groups.3 Once-daily oral amycretin appeared to have an acceptable safety profile and was tolerable in all tested doses, with TEAEs in line with what was expected from targeting GLP-1 and amylin receptors.3 All reported TEAEs occurred in a dose-proportional manner, were mild to moderate in severity, and mostly gastrointestinal. No new safety signals appeared during the study.3 Based on the findings from the oral and subcutaneous amycretin trials, Novo Nordisk recently announced it will advance amycretin into phase 3 trials to further investigate the treatment as a potential new therapeutic option for weight management.4 About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with overweight or obesity and for adults with type 2 diabetes. Amycretin is developed for subcutaneous and oral administration. Oral amycretin Phase 1 trial – The trial evaluated the single-ascending dose and multiple ascending doses for oral amycretin, up to 2 times 50 mg, in 144 people with overweight or obesity, with a total treatment duration of up to 12 weeks. Subcutaneous amycretin Phase 1b/2a trial – The trial investigated the safety, tolerability, pharmacokinetics, and proof-of-concept of once-weekly subcutaneous amycretin in 125 people with overweight or obesity. The trial was a combined single ascending dose, multiple ascending dose and dose-response trial investigating three different maintenance doses with a total treatment duration of up to 36 weeks. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information _______________________ References The Lancet: Dahl K, Toubro, S, Dey S, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: Results of a randomised, controlled, phase 1b/2a study. Dahl, K, et al. (2025). Amycretin, a Novel, Unimolecular GLP-1 and Amylin Receptor Agonist: Results of a Phase 1b/2a Clinical Trial. Poster 2002-LB. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025. The Lancet: Gasiorek A, Heydorn A, Gabery S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, randomised, placebo-controlled study. Novo Nordisk Company Announcement. Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development. Available at: Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
